Table 3.
Select clinical outcomes by prophylaxis group
| Clinical outcomes | Fluconazole group (n = 65) | Posaconazole group (n = 65) | P-value |
|---|---|---|---|
| Persistent fever unresponsive to broad-spectrum antibiotic treatment for ≥72 h, no (%) | 40 (61.5) | 18 (27.7) | <0.0001 |
| Fever, no (%) | 63 (96.9) | 64 (98.5) | 0.56 |
| Switch to other systemic antifungal therapy as empirical or preemptive therapy, number of patients (%) | 37 (56.9) | 28 (43.1) | 0.12 |
| Pneumonia and lung infiltrates indicative of invasive fungal infections shown on CT, no of patients (%) | 15 (23.1) | 10 (15.4) | 0.27 |
| ICU admission, no (%) | 9 (13.9) | 7 (10.8) | 0.60 |
| Inpatient length of stay days, mean ± SD | 33.4 ± 19.7 | 33.3 ± 13.3 | 0.97 |
| 100-day mortality, no (%) | 15 (23.1) | 16 (25.8)1 | 0.72 |
1
Three subjects in the posaconazole group were lost to follow-up at 100 days. SD, standard deviation.